神经损伤与功能重建2024，Vol.19Issue(4)：242-246,5.DOI:10.16780/j.cnki.sjssgncj.20230252
特拉唑嗪:通过调节磷酸甘油酸酯激酶1防治帕金森病
Terazosin:A potential Method of Treatment and Prevention of Parkinson's Disease through Phosphoglycerate Kinase1
摘要
Abstract
Terazosin,as a derivative of prazosin,is a long-acting selective α 1 adrenal receptor blocker,which is widely used in the treatment of hypertension and benign prostatic hyperplasia due to its good water solubility,high bioavailability and long half-life.Recent studies have found that TZ can activate intracellular phosphoglycerate kinase1(Pgk1)in a specific dose range to protect the neurons and may be beneficial for the treatment and prevention of Parkinson's disease(PD).This effect may be related to the improvement of cell energy metabolism,the increase of intracellular ATP concentration and the activation of Hsp90 caused by the activation of Pgk1.This indicates a new clinical application prospect of terazosin.This article will review and summarize the research progress of TZ in the newly discovered pharmacological mechanism and potential clinical application prospect,and discuss the possible research direction in the future.关键词
特拉唑嗪/帕金森病/磷酸甘油酸酯激酶1Key words
Terazosin/Parkinson's disease/phosphoglycerate kinase1分类
医药卫生引用本文复制引用
付余,聂昊,毛如雪,郑凯..特拉唑嗪:通过调节磷酸甘油酸酯激酶1防治帕金森病[J].神经损伤与功能重建,2024,19(4):242-246,5.基金项目
国家自然科学基金(丰富环境通过DNA甲基化调控Foxd3/miR-135a-5p通路改善AD小鼠学习记忆的机制研究,No.82371442) （丰富环境通过DNA甲基化调控Foxd3/miR-135a-5p通路改善AD小鼠学习记忆的机制研究,No.82371442）
